These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 28895119)

  • 41. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.
    Jiang C; Xie C; Li F; Zhang L; Nichols RG; Krausz KW; Cai J; Qi Y; Fang ZZ; Takahashi S; Tanaka N; Desai D; Amin SG; Albert I; Patterson AD; Gonzalez FJ
    J Clin Invest; 2015 Jan; 125(1):386-402. PubMed ID: 25500885
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hematopoietically expressed homeobox is a target gene of farnesoid X receptor in chenodeoxycholic acid-induced liver hypertrophy.
    Xing X; Burgermeister E; Geisler F; Einwächter H; Fan L; Hiber M; Rauser S; Walch A; Röcken C; Ebeling M; Wright MB; Schmid RM; Ebert MP
    Hepatology; 2009 Mar; 49(3):979-88. PubMed ID: 19072826
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cellular cholesterol accumulation modulates high fat high sucrose (HFHS) diet-induced ER stress and hepatic inflammasome activation in the development of non-alcoholic steatohepatitis.
    Bashiri A; Nesan D; Tavallaee G; Sue-Chue-Lam I; Chien K; Maguire GF; Naples M; Zhang J; Magomedova L; Adeli K; Cummins CL; Ng DS
    Biochim Biophys Acta; 2016 Jul; 1861(7):594-605. PubMed ID: 27090939
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Defective FXR-SHP Regulation in Obesity Aberrantly Increases
    Seok S; Sun H; Kim YC; Kemper B; Kemper JK
    Diabetes; 2021 Mar; 70(3):733-744. PubMed ID: 33328206
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation.
    Carino A; Marchianò S; Biagioli M; Fiorucci C; Zampella A; Monti MC; Morretta E; Bordoni M; Di Giorgio C; Roselli R; Ricci P; Distrutti E; Fiorucci S
    Nutrients; 2019 May; 11(5):. PubMed ID: 31117231
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Altered cellular redox status, sirtuin abundance and clock gene expression in a mouse model of developmentally primed NASH.
    Bruce KD; Szczepankiewicz D; Sihota KK; Ravindraanandan M; Thomas H; Lillycrop KA; Burdge GC; Hanson MA; Byrne CD; Cagampang FR
    Biochim Biophys Acta; 2016 Jul; 1861(7):584-93. PubMed ID: 27040510
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CCAAT/enhancing binding protein beta deletion in mice attenuates inflammation, endoplasmic reticulum stress, and lipid accumulation in diet-induced nonalcoholic steatohepatitis.
    Rahman SM; Schroeder-Gloeckler JM; Janssen RC; Jiang H; Qadri I; Maclean KN; Friedman JE
    Hepatology; 2007 May; 45(5):1108-17. PubMed ID: 17464987
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Epigallocatechin gallate attenuated non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet.
    Ding Y; Sun X; Chen Y; Deng Y; Qian K
    Eur J Pharmacol; 2015 Aug; 761():405-12. PubMed ID: 25967348
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Chow MD; Lee YH; Guo GL
    Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cyclosporin A induced toxicity in mouse liver slices is only slightly aggravated by Fxr-deficiency and co-occurs with upregulation of pro-inflammatory genes and downregulation of genes involved in mitochondrial functions.
    Szalowska E; Pronk TE; Peijnenburg AA
    BMC Genomics; 2015 Oct; 16():822. PubMed ID: 26482353
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Obeticholic Acid Ameliorates Valproic Acid-Induced Hepatic Steatosis and Oxidative Stress.
    Gai Z; Krajnc E; Samodelov SL; Visentin M; Kullak-Ublick GA
    Mol Pharmacol; 2020 May; 97(5):314-323. PubMed ID: 32098797
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver.
    Zollner G; Wagner M; Fickert P; Geier A; Fuchsbichler A; Silbert D; Gumhold J; Zatloukal K; Kaser A; Tilg H; Denk H; Trauner M
    Am J Physiol Gastrointest Liver Physiol; 2005 Nov; 289(5):G798-805. PubMed ID: 16002565
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Activation of farnesoid X receptor promotes triglycerides lowering by suppressing phospholipase A2 G12B expression.
    Liu Q; Yang M; Fu X; Liu R; Sun C; Pan H; Wong CW; Guan M
    Mol Cell Endocrinol; 2016 Nov; 436():93-101. PubMed ID: 27471003
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice.
    Hye Khan MA; Schmidt J; Stavniichuk A; Imig JD; Merk D
    Biochem Pharmacol; 2019 Aug; 166():212-221. PubMed ID: 31129048
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of chemerin as a novel FXR target gene down-regulated in the progression of nonalcoholic steatohepatitis.
    Deng Y; Wang H; Lu Y; Liu S; Zhang Q; Huang J; Zhu R; Yang J; Zhang R; Zhang D; Shen W; Ning G; Yang Y
    Endocrinology; 2013 May; 154(5):1794-801. PubMed ID: 23507574
    [TBL] [Abstract][Full Text] [Related]  

  • 56. IL-19 Contributes to the Development of Nonalcoholic Steatohepatitis by Altering Lipid Metabolism.
    Azuma YT; Fujita T; Izawa T; Hirota K; Nishiyama K; Ikegami A; Aoyama T; Ike M; Ushikai Y; Kuwamura M; Fujii H; Tsuneyama K
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944021
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The nuclear receptor FXR, but not LXR, up-regulates bile acid transporter expression in non-alcoholic fatty liver disease.
    Aguilar-Olivos NE; Carrillo-Córdova D; Oria-Hernández J; Sánchez-Valle V; Ponciano-Rodríguez G; Ramírez-Jaramillo M; Chablé-Montero F; Chávez-Tapia NC; Uribe M; Méndez-Sánchez N
    Ann Hepatol; 2015; 14(4):487-93. PubMed ID: 26019035
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis.
    Li J; Liu M; Li Y; Sun DD; Shu Z; Tan Q; Guo S; Xie R; Gao L; Ru H; Zang Y; Liu H; Li J; Zhou Y
    J Med Chem; 2020 Nov; 63(21):12748-12772. PubMed ID: 32991173
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Isotschimgine alleviates nonalcoholic steatohepatitis and fibrosis via FXR agonism in mice.
    Li J; Liu C; Zhou Z; Dou B; Huang J; Huang L; Zheng P; Fan S; Huang C
    Phytother Res; 2021 Jun; 35(6):3351-3364. PubMed ID: 33784797
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Population-based meta-analysis and gene-set enrichment identifies FXR/RXR pathway as common to fatty liver disease and serum lipids.
    Handelman SK; Puentes YM; Kuppa A; Chen Y; Du X; Feitosa MF; Palmer ND; Speliotes EK
    Hepatol Commun; 2022 Nov; 6(11):3120-3131. PubMed ID: 36098472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.